Ethnic differences in acetylcholinesterase inhibitor use for Alzheimer disease.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 16009909.
- Also identified by PMC identifier 2830864.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Acetylcholinesterase inhibitors (AChIs) have been demonstrated to improve Alzheimer disease symptoms. Whether the use of AChIs varies by ethnicity is unknown. More than 2500 ethnically diverse patients (6% African American, 14% Latino, and 7% Asian patients) from the Alzheimer's Disease Research Centers in California were studied. Compared with white patients with AD, minority patients had 40% lower odds of AChI use (odds ratio 0.6, 95% confidence interval: 0.5 to 0.7).
Medical subject headings
- Alzheimer Disease
- Brain
- Brain Chemistry
- Cholinesterase Inhibitors